Former site of US Compounding is acquired by up-and-comer in custom compounded pharmaceuticals, FarmaKeio, as part of ongoing expansion to support availability and delivery of custom compounded medications nationwide.
Read Press ReleaseCommonsense Online and Mobile Approach to Identifying and Engaging With Drug Manufacturers to Meet DSCSA Requirements — Including Drop Shipment Transactions
Read Press ReleaseNew biologics outsourcing solution provider leverages proven track record of Tanvex BioPharma USA Inc. to help early-stage companies bring mammalian and microbial derived biologics from concept to commercialization.
Read Press ReleaseSenzo Health Limited (London, UK) ("Senzo"), a life sciences company developing high-accuracy, low-cost, point-of-care diagnostic technologies, this week announced an additional $1.8m investment for its breakthrough Amplified Lateral Flow (ALF) test technology, advancing its mission to bring high-quality, affordable tests into the home.
Read Press ReleaseThe leader in ADHD assessments will feature a series of podcasts and webinars covering ADHD resources, insights, discussions, destigmatization efforts for this condition, and the pursuit of optimal ADHD treatment.
Read Press ReleaseA recent publication in "Cancer Discovery" reviewed Germline BRCA-associated pancreatic ductal adenocarcinoma (glBRCA PDAC) spectrum of responses to platinum and PARPi therapy, exploring the genomic and clinical features that may lead to different responses, and investigates the mechanisms of resistance.
Read Press ReleaseDr. William Rust will give an oral presentation on Seraxis’ proprietary technology for the production of therapeutic pancreatic organoids from pancreas-derived stem cells, as well as review initial diabetes model data of functional cure of Type 1 Diabetes. Seraxis’ presentation, entitled “Stem-cell Derived Islets for Treating Diabetes”, will be delivered in the session entitled "Transplantation of Islet and Stem Cells Today and Tomorrow".
Read Press ReleaseFollowing the launch of its Marketplace in 2022, Hyris continues to leverage the AI capabilities of its genetic testing platform, renowned for its adaptability, to support both researchers and kit developers worldwide. New onboarding programs enable emerging players to accelerate their go-to-market, as well as established manufacturers and diagnostic providers to integrate their portfolio with ease, maximizing their cost-per-value strategy.
Read Press ReleaseLeadership team expanded with addition of Chief Corporate Development Officer, Ted Hibben, a 25-year venture-stage business development biotherapeutic industry veteran
Total venture funding tops $50M to date
Amelia™-1 Study is testing if evexomostat can improve patients' safety and clinical response to a PI3K inhibitor plus an estrogen receptor degrader. Evexomostat, a novel MetAP2 inhibitor, controlled PI3K-induced hyperglycemia in the first study patient, consistent with pre-clinical data. Further, ctDNA data shows no evidence of residual PIK3CA mutation in blood after 6 weeks of treatment.
Read Press ReleaseBrainify.AI, an innovative company leveraging artificial intelligence to revolutionize the treatment of depression, is excited to announce it has joined Johnson & Johnson Innovation JLABS (JLABS) as a resident company. This marks a significant milestone for Brainify.AI and is another indication of the value and promise the company brings to the medical AI field.
Read Press ReleaseA University of Chicago team identified a special type of stem cell that heals damaged bowel tissue in mice, a discovery that may have direct application to humans with inflammatory bowel disease. These early findings, made possible with seed funding from the GI Research Foundation, resulted in a recent five-year, $2.5 million grant from the National Institutes of Health to study those cells in humans.
Read Press ReleaseCMX-2043, a novel, proprietary cytoprotective drug candidate, demonstrated excellent safety and tolerability in a Phase 1 single ascending and multiple ascending dose (SAD-MAD) clinical trial. CMX-2043 has previously demonstrated safety and efficacy in extensive preclinical pharmacology, toxicology and TBI translational studies. CMX-2043 will be Phase 2-ready by the first quarter of 2024.
Read Press ReleasePA-based clinical technology provider assisTek has announced new features to its upcoming software release, including AI Integration, a Proprietary OS, SSO & Remote Provisioning, to add to its growing suite of eCOA & ePRO solutions.
Read Press Release